CANDEL THERAPEUTICS INC (CADL) — insider trading
Health Care · NASDAQ
CANDEL THERAPEUTICS INC (CADL) has 24 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 24 (latest 2026-09-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Loggia Nicoletta | Director | Grant / award / vesting (derivative) | 380 | $8.68 | $3.3K | Form 4 |
| 2026-09-30 | PAPA JOSEPH C | Director | Grant / award / vesting (derivative) | 1,325 | $8.68 | $11.5K | Form 4 |
| 2026-09-30 | Manning Paul B | Director | Grant / award / vesting (derivative) | 2,189 | $8.68 | $19.0K | Form 4 |
| 2026-09-11 | Tak Paul Peter | Director, Officer (Chief Executive Officer) | Open-market sale | 59,379 | $10.46 | $620.9K | Form 4 |
| 2026-09-10 | Tak Paul Peter | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 125,000 | — | $0 | Form 4 |
| 2026-09-10 | Tak Paul Peter | Director, Officer (Chief Executive Officer) | Open-market sale | 220,866 | $11.50 | $2.54M | Form 4 |
| 2026-09-10 | Tak Paul Peter | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 125,000 | $1.55 | $193.8K | Form 4 |
| 2026-09-08 | Zimmermann Martine | Director | Grant / award / vesting (derivative) | 64,000 | — | $0 | Form 4 |
| 2026-08-17 | Tyagarajan Seshu | Officer (Chief Technology Officer) | Open-market sale | 7,000 | $12.00 | $84.0K | Form 4 |
| 2026-07-06 | Sims Mark E. | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 285,000 | — | $0 | Form 4 |
| 2026-06-30 | Loggia Nicoletta | Director | Grant / award / vesting (derivative) | 381 | $8.64 | $3.3K | Form 4 |
| 2026-06-30 | PAPA JOSEPH C | Director | Grant / award / vesting (derivative) | 1,331 | $8.64 | $11.5K | Form 4 |
| 2026-06-30 | Manning Paul B | Director | Grant / award / vesting (derivative) | 2,199 | $8.64 | $19.0K | Form 4 |
| 2026-06-29 | Tyagarajan Seshu | Officer (Chief Technology Officer) | Open-market sale | 7,000 | $10.02 | $70.2K | Form 4 |
| 2026-06-29 | Barone Francesca | Officer (Chief Scientific Officer) | Open-market sale | 23,447 | $10.06 | $235.8K | Form 4 |
| 2026-06-23 | Manning Paul B | Director | Grant / award / vesting (derivative) | 32,000 | — | $0 | Form 4 |
| 2026-06-23 | Nguyen Diem | Director | Grant / award / vesting (derivative) | 32,000 | — | $0 | Form 4 |
| 2026-06-23 | Nabel Gary J. | Director | Grant / award / vesting (derivative) | 32,000 | — | $0 | Form 4 |
| 2026-06-23 | Gaeta Renee | Director | Grant / award / vesting (derivative) | 32,000 | — | $0 | Form 4 |
| 2026-06-23 | Martell Christopher | Director | Grant / award / vesting (derivative) | 32,000 | — | $0 | Form 4 |
| 2026-06-23 | Benz Edward J. JR | Director | Grant / award / vesting (derivative) | 32,000 | — | $0 | Form 4 |
| 2026-06-23 | PAPA JOSEPH C | Director | Grant / award / vesting (derivative) | 32,000 | — | $0 | Form 4 |
| 2026-06-23 | Loggia Nicoletta | Director | Grant / award / vesting (derivative) | 32,000 | — | $0 | Form 4 |
| 2026-06-23 | Radhakrishnan Maha | Director | Grant / award / vesting (derivative) | 32,000 | — | $0 | Form 4 |
Ask the chat about CADL's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CANDEL THERAPEUTICS INC (CADL).
Last updated 2026-09-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.